Logo
x

Search

Subscribe Now

Galapagos

Galapagos Receives the US FDA’s IND Clearance of GLPG5101 to Treat R/R Non-Hodgkin lymphoma (NHL)

Galapagos Receives the US FDA’s IND Clearance of GLPG5101 to Treat R/R Non-Hodgkin lymphoma (NHL)

  • August 23, 2024
Galapagos Reports the First Patient Dosing of GLPG3667 in the P-II Study (GALARISSO) for the Treatment of Dermatomyositis

Galapagos Reports the First Patient Dosing of GLPG3667 in the P-II Study (GALARISSO) for the Treatment of Dermatomyositis

  • May 24, 2023
Galapagos Reports Initiation of P-III Trial (OLINGUITO) for Filgotinib to Treat Active Axial Spondyloarthritis

Galapagos Reports Initiation of P-III Trial (OLINGUITO) for Filgotinib to Treat Active Axial Spondyloarthritis

  • April 28, 2023
Galapagos Reports P-III Trial (DIVERSITY) Results of Filgotinib for the Treatment of Crohn’s Disease

Galapagos Reports P-III Trial (DIVERSITY) Results of Filgotinib for the Treatment of Crohn’s Disease

  • February 9, 2023
Galapagos to Acquire CellPoint and AboundBio to Advance Cell Therapies for the Treatment of Advanced Cancer

Galapagos to Acquire CellPoint and AboundBio to Advance Cell Therapies for the Treatment of Advanced Cancer

  • June 22, 2022
Galapagos Reports Completion of Patient Enrollment in P-II MANGROVE Trial of GLPG2737 for the Treatment of Polycystic Kidney Disease

Galapagos Reports Completion of Patient Enrollment in P-II MANGROVE Trial of GLPG2737 for the Treatment of Polycystic Kidney Disea...

  • November 24, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.